As the initiators of antigen-specific immune responses, dendritic cells (DCs) play a central role in regulating the balance between CD8^+^ T-cell immunity and tolerance to tumor-associated antigens (TAAs). The tumor microenvironment often recruits immunosuppressive cells and releases soluble factors that attenuate the activity of DCs, such as vascular endothelial growth factor (VEGF), indoleamine 2,3-dioxygenase 1 (IDO1), arginase, transforming growth factor β1 (TGFβ1), and prostaglandins, hence limiting the therapeutic potential of DC-based anticancer vaccines.[@R1]^-^[@R3] With the exception of sipuleucel-T (Provenge^®^), current DC-based vaccines remain unsuccessful, and one major obstacle in this sense is the immunosuppressive activity of host DCs. Cross-priming, the process whereby DCs activate CD8^+^ T cells by cross-presenting TAAs on MHC class I molecules, plays a major role in generating antitumor CD8^+^ T-cell immunity.[@R4]^,^[@R5] However, the DC compartment of tumor-bearing hosts is often defective or tolerogenic, being unable to induce productive CD8^+^ T-cell responses upon TAA cross-presentation.[@R4] While some chemotherapeutic regiments are well known to promote the cross-presentation of TAAs,[@R2]^,^[@R4] whether and how neoplastic cells directly interfere with cross-priming to suppress antitumor CD8^+^ T-cell immunity has not been elucidated until recently.

We and others have previously shown that β-catenin regulates DC-mediated CD4^+^ T-cell responses and promotes T-cell tolerance in murine models of autoimmune diseases,[@R6]^,^[@R7] suggesting that β-catenin serves as a tolerizing signal that shifts the balance between CD4^+^ T-cell immunity and tolerance. Although these studies primarily examined the function of CD4^+^ T cells, tumors likely employ similar mechanisms to influence DC-mediated CD8^+^ T-cell immunity vs. tolerance. We thus wondered whether β-catenin signaling in DCs also suppresses antitumor CD8^+^ T-cell immunity, and---if so---how neoplastic cells might harness β-catenin to suppress antitumor CD8^+^ T-cell responses. We found elevated expression levels of β-catenin in DCs from mice bearing B16 melanomas.[@R8] The tumor-mediated upregulation of β-catenin in DCs appears to be systemic, as opposed to local, since elevated β-catenin levels were observed not only in DCs isolated from tumor-draining lymph nodes, but also in splenic DCs and DCs obtained from mesenteric lymph nodes. Exposing DCs to tumor-conditioned culture media in vitro also led to upregulation of β-catenin, suggesting that this effect is due (at least in part) to the release of one or more soluble factors by malignant cells. A genetic manipulation that resulted in the constitutive activation of β-catenin in DCs (DC-β-catenin^active^ mice) significantly accelerated tumor growth in multiple models of neoplasia, suggesting that the activation of β-catenin in DCs negatively regulates antitumor immunity.

Both tumor-bearing and DC-β-catenin^active^ mice, when vaccinated with a DC-targeting monoclonal antibody (specific for lymphocyte antigen 75, LY75, best known as DEC-205) fused with model antigen ovalbumin (OVA), exhibited impaired primary and recall OVA-specific CD8^+^ T-cell responses, suggesting that activation of β-catenin in DCs (be it genetic or induced by tumors) negatively regulates CD8^+^ T-cell immunity. Both tumor-bearing and DC-β-catenin^active^ mice were deficient in cross-priming but not cross-presentation, as measured by antigen presentation assays in vivo. In addition, antigen-specific CD8^+^ T cells primed in DC-β-catenin^active^ and tumor-bearing mice mediated suboptimal CD8^+^ memory responses when transferred into naïve wild-type mice, suggesting that deficiencies in the cross-priming phase contribute to dampened CD8^+^ T-cell immunity. Further studies revealed that such a deficiency in cross-priming is DC-intrinsic, as DCs isolated from immunized DC-β-catenin^active^ and tumor-bearing mice also exhibited impaired cross-priming when cultured with OVA-specific CD8^+^ T cells *ex vivo.* Importantly, the DC-specific deletion of the β-catenin-coding gene (DC-β-catenin^−/−^ mice) completely abrogated tumor-induced inhibition of cross-priming, confirming that this immunosuppressive pathway is dependent on β-catenin. Thus, neoplastic cells activate β-catenin in DCs to inhibit cross-priming, hence impairing CD8^+^ T-cell immunity. Given the importance of cross-priming in generating antitumor CD8^+^ T cell-mediated immune responses, our findings suggest that the activation of β-catenin in DCs may serve as a general mechanism for tumors to evade immunosurveillance.

We further asked whether β-catenin-mediated inhibition of cross-priming is reversible, and---if so---whether enhancing cross-priming results in restored antitumor CD8^+^ T-cell immunity. By testing various approaches to the use of Toll-like receptor agonists as adjuvants, we were able to select an immunization protocol that restored cross-priming in DC-β-catenin^active^ mice. Not surprisingly, CD8^+^ memory responses were also restored in these mice, suggesting that the β-catenin-dependent inhibition of cross-priming can be reversed to restore impaired CD8^+^ immunity. As β-catenin might similarly impair the ability of DCs to activate CD8^+^ memory T cells during the recall phase, we reasoned that enhancing cross-priming during the recall phase might restore CD8^+^ memory responses. Indeed, in both DC-β-catenin^active^ and tumor-bearing mice, CD8^+^ immunity was substantially boosted upon recall with antigens that favor cross-priming. These findings indicate that strong antitumor CD8^+^ immunity can be achieved upon recall with agents that promote cross-priming even when the initial DC-based vaccines fail, offering a new approach to improve DC-based anticancer vaccines that elicit weak antitumor responses. Further studies are warranted to examine whether these approaches are applicable to various DC-based vaccines.

Understanding how β-catenin regulates the ability of DCs to cross-prime antigen specific CD8^+^ T cells requires further studies, although the maturation state of DCs and their cytokine production profile are likely involved.[@R6]^,^[@R7] Interestingly, TADCs have recently been shown to express elevated levels of both β-catenin and forkhead box O3 (FOXO3). FOXO3 appears to render TADCs tolerogenic and to induce an immunosuppressive activity in tumor-specific CD8^+^ T cells, presumably as it influences the maturation state of DCs and their cytokine production pattern.[@R9] An evolutionarily conserved interaction between β-catenin and FOXO3 has been shown to regulate the transcriptional activity of both FOXO3 and β-catenin/T-cell factor (TCF),[@R10] suggesting a scenario in which the crosstalk between FOXO3 and β-catenin in DCs ultimately determines DC function ([Fig. 1](#F1){ref-type="fig"}).

![**Figure 1.** Tumors suppress CD8^+^ T-cell immunity by a β-catenin-dependent pathway that inhibits cross-priming. Tumors activate β-catenin in dendritic cells (DCs), most likely through the release of one or more soluble factors. The activation of β-catenin in DCs inhibits the cross-priming of antigen-specific CD8^+^ T cells, dampening both primary and recall CD8^+^ T-cell responses. The DC-specific deletion of the β-catenin-coding gene completely abrogates the ability of malignant cells to inhibit cross-priming. β-catenin-dependent inhibition of cross-priming is reversible, as cross-priming can be restored by modifying immunization protocols. Thus, CD8^+^ T-cell immunity can be rescued by enhancing cross-priming at the priming or recall stage. Tumor-associated dendritic cells (TADCs) also exhibit increased expression levels of forkhead box O3 (FOXO3), and the cross-talk between FOXO3 and β-catenin likely determines the function of this DC subset.](onci-2-e26920-g1){#F1}
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